Xellia Pharmaceuticals ApS
Xellia Pharmaceuticals is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS) built on more than 100 years’ pharmaceutical industry experience. Headquartered in Copenhagen, Denmark and owned by Novo A/S, Xellia Pharmaceuticals has more than 1200 employees globally.
From manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers.
China is a very important part of Xellia’s global strategy. In China, Xellia’s sales office is located in Shanghai and production site in Taizhou. Xellia’s production establishment in China is based on a joint-venture with Hisun Pharmaceuticals. At the Taizhou site Xellia is producing critical life-saving anti-infectives Vancomycin, Bacitracin and Bacitracin Zinc. With advanced technology from Xellia and an cGMP record, the products produced at the Taizhou site are sold to internationally recognized pharmaceutical companies.